FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like How to Write the Best Cover Letter for a Research Scientist Job February 15, 2017 Former Schering-Plough CEO Says This is the 'Worst Solution' to the Drug Pricing Dilemma August 24, 2017 Novel Material Made Of Living Cells Glows When Touching Certain Chemical Compounds, MIT Study Reveals February 19, 2017
Former Schering-Plough CEO Says This is the 'Worst Solution' to the Drug Pricing Dilemma August 24, 2017
Novel Material Made Of Living Cells Glows When Touching Certain Chemical Compounds, MIT Study Reveals February 19, 2017
